CVS HEALTH Corp (CVS) Insider Transactions
Over the last 12 months, 22 CVS HEALTH Corp (CVS) insiders filed 72 SEC Form 4 transactions — $0 in open-market purchases ( 0 distinct buyers) and $362.5M in open-market sales. 0% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $362.5MOpen-market sells (1y)
- 22Distinct insiders
- 72Transactions filed
- 0%Under Rule 10b5-1 plan
- 2026-05-31Latest filing
Recent Form 4 Filings Most recent 50 of 72 (1-year window)
Each row is a single Form 4 filing event for CVS, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-05-31 | Newman Brian | EVP, Chief Financial Officer | Other | F | $225.4K | 2,478 | $90.98 |
| 2026-05-31 | Compton-Phillips Amy | EVP, Chief Medical Officer | Other | F | $693.1K | 7,618 | $90.98 |
| 2026-05-21 | ROBBINS LARRY | — | Sell | S | $34.6M | 370,462 | $93.45 |
| 2026-05-21 | ROBBINS LARRY | — | Sell | S | $35.3M | 378,000 | $93.31 |
| 2026-05-21 | AGUIRRE FERNANDO | — | Sell | D | $146.1K | 1,563 | $93.50 |
| 2026-05-20 | ROBBINS LARRY | — | Sell | S | $74.6M | 797,628 | $93.48 |
| 2026-05-20 | ROBBINS LARRY | — | Sell | S | $14.5M | 152,691 | $94.81 |
| 2026-05-20 | ROBBINS LARRY | — | Sell | S | $6.4M | 66,881 | $95.67 |
| 2026-05-20 | ROBBINS LARRY | — | Sell | S | $77.0K | 800 | $96.28 |
| 2026-05-20 | AGUIRRE FERNANDO | — | Sell | D | $2.9M | 30,437 | $93.78 |
| 2026-05-19 | ROBBINS LARRY | — | Sell | S | $187.3M | 1,983,387 | $94.45 |
| 2026-05-19 | ROBBINS LARRY | — | Sell | S | $14.4K | 151 | $95.18 |
| 2026-05-14 | Gallina John E | — | Grant | A | $140.6K | 1,448 | $97.15 |
| 2026-05-14 | Mahoney Michael F | — | Grant | A | $168.7K | 1,737 | $97.15 |
| 2026-05-14 | AGUIRRE FERNANDO | — | Grant | A | $151.8K | 1,563 | $97.15 |
| 2026-05-14 | Balser Jeffrey R. | — | Grant | A | $199.9K | 2,058 | $97.15 |
| 2026-05-14 | KIRBY J SCOTT | — | Grant | A | $140.6K | 1,447 | $97.15 |
| 2026-05-14 | Norwalk Leslie V | — | Grant | A | $140.6K | 1,447 | $97.15 |
| 2026-05-14 | SANSONE GUY P | — | Grant | A | $140.6K | 1,447 | $97.15 |
| 2026-05-14 | DECOUDREAUX ALECIA A | — | Grant | A | $140.6K | 1,448 | $97.15 |
| 2026-05-14 | Finucane Anne A. | — | Grant | A | $150.0K | 1,544 | $97.15 |
| 2026-05-14 | BROWN C DAVID II | — | Grant | A | $150.0K | 1,544 | $97.15 |
| 2026-05-14 | Shulman Douglas H. | — | Grant | A | $140.6K | 1,448 | $97.15 |
| 2026-05-14 | ROBBINS LARRY | — | Grant | A | $187.5K | 1,930 | $97.15 |
| 2026-05-08 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | Sell | S | $6.2M | 69,551 | $89.58 |
| 2026-04-01 | Shah Prem S | EVP and Group President | Other | F | $107.6K | 1,484 | $72.49 |
| 2026-04-01 | Nelson Steven H | EVP and President, Aetna | Other | F | $176.3K | 2,432 | $72.49 |
| 2026-04-01 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | Other | F | $263.4K | 3,634 | $72.49 |
| 2026-04-01 | Khichi Samrat S. | EVP, CPO and General Counsel | Other | F | $256.7K | 3,541 | $72.49 |
| 2026-04-01 | Joyner J. David | President, CEO and Chair | Other | F | $582.0K | 8,029 | $72.49 |
| 2026-04-01 | Clark James David | SVP, Cont & Chief Acct Officer | Other | F | $236.5K | 3,262 | $72.49 |
| 2026-04-01 | CAPOZZI HEIDI B | EVP and Chief People Officer | Other | F | $96.7K | 1,334 | $72.49 |
| 2026-03-31 | Shah Prem S | EVP and Group President | Grant | A | $1.8M | 25,062 | $71.82 |
| 2026-03-31 | Shah Prem S | EVP and Group President | Grant | A | $11.6M | 161,676 | $71.82 |
| 2026-03-31 | Newman Brian | EVP, Chief Financial Officer | Grant | A | $1.4M | 19,493 | $71.82 |
| 2026-03-31 | Newman Brian | EVP, Chief Financial Officer | Grant | A | $9.0M | 125,748 | $71.82 |
| 2026-03-31 | Nelson Steven H | EVP and President, Aetna | Grant | A | $1.6M | 22,277 | $71.82 |
| 2026-03-31 | Nelson Steven H | EVP and President, Aetna | Grant | A | $10.3M | 143,712 | $71.82 |
| 2026-03-31 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | Grant | A | $1.6M | 22,277 | $71.82 |
| 2026-03-31 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | Grant | A | $10.3M | 143,712 | $71.82 |
| 2026-03-31 | Khichi Samrat S. | EVP, CPO and General Counsel | Grant | A | $900.0K | 12,531 | $71.82 |
| 2026-03-31 | Khichi Samrat S. | EVP, CPO and General Counsel | Grant | A | $5.8M | 80,838 | $71.82 |
| 2026-03-31 | Joyner J. David | President, CEO and Chair | Grant | A | $6.2M | 86,326 | $71.82 |
| 2026-03-31 | Compton-Phillips Amy | EVP, Chief Medical Officer | Grant | A | $400.0K | 5,569 | $71.82 |
| 2026-03-31 | Compton-Phillips Amy | EVP, Chief Medical Officer | Grant | A | $2.6M | 35,928 | $71.82 |
| 2026-03-31 | Clark James David | SVP, Cont & Chief Acct Officer | Grant | A | $799.9K | 11,138 | $71.82 |
| 2026-03-31 | Clark James David | SVP, Cont & Chief Acct Officer | Grant | A | $860.1K | 11,976 | $71.82 |
| 2026-03-31 | CAPOZZI HEIDI B | EVP and Chief People Officer | Grant | A | $720.0K | 10,025 | $71.82 |
| 2026-03-31 | CAPOZZI HEIDI B | EVP and Chief People Officer | Grant | A | $4.6M | 64,670 | $71.82 |
| 2026-03-19 | Gallina John E | — | Grant | — | $41.8K | 582 | $71.86 |
Showing the most recent 50 of 72 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Methodology & FAQ
How We Track CVS Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for CVS HEALTH Corp?
Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of CVS HEALTH Corp (CVS) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of CVS HEALTH Corp (CVS) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.